Neximmune — Company Overview, News & Financial Data
Neximmune (NASDAQ:NEXI) is a biotechnology firm dedicated to pioneering new approaches in immunotherapy with a primary focus on cancer treatment and
Neximmune
About
Neximmune (NASDAQ:NEXI) is a biotechnology firm dedicated to pioneering new approaches in immunotherapy with a primary focus on cancer treatment and other serious diseases. The company's operations center around its proprietary Artificial Immune Modulation (AIM) technology, designed to harness the body's natural immune system to combat illness more effectively. Neximmune's projects include several development-stage therapies targeting a range of hematologic cancers and solid tumors, aiming to provide novel solutions in areas with significant unmet medical needs. The objective of Neximmune is to advance these therapies through clinical trials successfully, with the ultimate goal of achieving regulatory approval and improving patient outcomes. The firm's dedication to innovation and patient care drives its progress and development strategies.
Snapshot
Operations
Products and/or services of Neximmune
- AIM ACT platform, a novel therapy for preventing relapse in acute myeloid leukemia patients.
- NEXI-001, a candidate for acute myeloid leukemia targeting minor histocompatibility antigens.
- NEXI-002, designed for the treatment of multiple myeloma by targeting specific tumor antigens.
- Development of personalized immunotherapies using patient-specific tumor targets.
- Collaboration with leading pharmaceutical companies to enhance cell therapy products.
- Research into expanding the AIM ACT platform for solid tumors, aiming to revolutionize cancer treatment.
Neximmune executive team
- Mr. John Trainer M.B.A.Consultant
- Mr. Craig R. Jalbert CIRAPresident, Treasurer, CS, Principal Executive Officer, Financial Off, & Principal Accounting Off
- Ms. Karen HaslbeckHead of Human Resources
- Dr. Daniel P. BednarikSenior Vice President of Molecular Engineering & Protein Design
- Dr. Robert Douglas Knight M.D.Chief Medical Officer
- Mr. Chad RubinSenior Vice President of Corporate Affairs
- Dr. Jack A. Ragheb M.D., Ph.D.Senior Vice President of Translational Science
- Mr. Matthew SchillerHead of Business Development
GET YOUR GRAFA EDGE NOW
We'll switch on a 30-day Edge trial as a welcome gift